Skip to main content
. Author manuscript; available in PMC: 2024 Apr 1.
Published in final edited form as: Matrix Biol. 2023 Mar 11;118:92–109. doi: 10.1016/j.matbio.2023.03.005

Figure 1. Inhibiting autophagy via ATG5 knockdown in vitro or chloroquine (CQ) treatment in vivo blocks autophagic degradation of HAS2.

Figure 1.

(A) Representative western blot (WB) of HUVEC whole-cell lysates pretreated with scrambled siRNA (siScr) or siRNA targeting ATG5 (siATG5). (B) Quantification of ATG5, LC3-I and HAS2 from A. Statistical analyses were calculated via two-tailed Student’s t test (*p < 0.05, **p <0.01, ***p<0.001). (C) Representative IHC of heart tissue from wild-type mice fasted for 48 h ±chloroquine (50 mg/kg) injected i.p. 4 and 24 h prior to sacrifice. Has2 is labeled in red and Lc3 in green; nuclei are blue. Scale bar, 20 μm. D, quantification of Has2 fluorescence intensity from C; n = 6–8 biological replicates. Statistical analyses were calculated via One-way ANOVA (**p < 0.01, ***p < 0.001).